Page 30 of 31
PH9.1-7 | Miscellaneous Therapeutics — Assignment
CLINICAL SCENARIO
This assignment integrates the pharmacology of immunomodulators, toxicology and antidotes, antiseptics and disinfectants, dermatological drugs, ocular drugs, and vaccines. You will apply these concepts to realistic clinical scenarios encountered in Indian medical practice — transplant wards, rural poisoning emergencies, dermatology OPDs, eye departments, and immunisation programmes.
Instructions
Answer ALL FOUR sections. Each section carries a specific weightage. Write in complete sentences with clear pharmacological reasoning — avoid one-word answers. Where calculations are required, show your working. Where monitoring is requested, name the specific test and the reason for it. Total marks: 40. Time allowed: 90 minutes.
Length: Section A: 300–400 words; Section B: 350–450 words; Section C: 350–450 words; Section D: 350–450 words. Total: ~1400–1700 words.
What to Submit
A 40-year-old paddy farmer in a district hospital presents with severe bradycardia, copious bronchial secretions, miosis, muscle fasciculations, and altered consciousness. History suggests pesticide exposure. His oxygen saturation is 82%.
A 29-year-old woman with systemic lupus erythematosus (SLE) and nephritis is well-controlled on mycophenolate mofetil and hydroxychloroquine. She is now planning pregnancy and asks her physician about her medications and vaccination.
Grading Rubric — Miscellaneous Therapeutics Assignment Rubric
| Criterion | Points | Full-marks descriptor |
|---|---|---|
| Toxidrome recognition and mechanistic accuracy (PH9.2) — correctly identifies cholinergic toxidrome, names SLUDGE signs with receptor-level mechanism, correctly identifies BZD/sedative toxidrome with antidote caveats | 10 pts | Excellent: Both toxidromes identified with full mechanistic explanation; atropine endpoint correctly stated as 'drying of secretions' with reasoning; PAM ageing constraint explained; flumazenil caution (withdrawal seizures in BZD-dependent) named. |
| Immunomodulator and vaccine pharmacology (PH9.1, PH9.4) — MMF mechanism and teratogenicity; HCQ in pregnancy; MMR timing; active vs passive immunity distinction | 10 pts | Excellent: MMF IMPDH inhibition → lymphocyte arrest explained; Category D/X stated; azathioprine switch recommended; HCQ continued (fetal protection); MMR timing relative to pregnancy and immunosuppression addressed; active vs passive immunity clearly distinguished with onset, duration, and scenario. |
| Chelation and dermatological pharmacology (PH9.3, PH9.6) — correct chelator-metal matching; isotretinoin counselling with teratogenicity basis; MTX weekly dosing explained | 10 pts | Excellent: DMSA for paediatric lead (oral, SH-binding) and D-penicillamine for Wilson's (copper; copper excretion mechanism) correctly paired; adverse effects named; isotretinoin teratogenicity (RAR-mediated developmental gene disruption) explained; two monitoring parameters correct; MTX weekly dosing rationale (cancer vs inflammatory dosing difference) explained. |
| Antiseptics and ocular pharmacology (PH9.5, PH9.7) — correct antiseptic selection for each use with mechanism; latanoprost mechanism and ADRs; rational drug addition for glaucoma | 10 pts | Excellent: Chlorhexidine for hand antisepsis (protein binding + residual activity explained); povidone-iodine or chlorhexidine for operative site; autoclave/glutaraldehyde for instruments (Spaulding-critical); Dettol undiluted toxicity explained (tissue damage, barrier disruption); latanoprost FP-receptor mechanism + uveoscleral outflow; three local ADRs named (iris pigmentation, lash growth, fat atrophy); timolol as rational add-on (different mechanism, production ↓); brimonidine as acceptable alternative. |